KALA BIO, INC. Deferred Tax Assets, Operating Loss Carryforwards
KALA BIO, INC. (KALA) had Deferred Tax Assets, Operating Loss Carryforwards of $131.29 million as of 2025-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-04-15
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $131.29M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $121.14M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $108.92M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $102.56M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2025-12-31 | $131.29M 10-K · filed 2026-04-15 |
| 2024-12-31 | $121.14M 10-K · filed 2026-04-15 |
| 2023-12-31 | $108.92M 10-K · filed 2025-03-31 |
| 2022-12-31 | $102.56M 10-K · filed 2024-03-29 |
| 2021-12-31 | $102.94M 10-K · filed 2023-03-03 |
| 2020-12-31 | $67.37M 10-K · filed 2022-03-29 |
| 2019-12-31 | $49.02M 10-K · filed 2021-02-25 |
| 2018-12-31 | $46.93M 10-K · filed 2020-02-12 |
| 2017-12-31 | $33.69M 10-K · filed 2019-03-12 |
| 2016-12-31 | $36.28M 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |